We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.475 | 1.45 | 1.50 | 1.475 | 1.475 | 1.475 | 92,876 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 4.47M | -40.44M | -0.0522 | -0.28 | 11.4M |
From Apr 2019 to Apr 2024
TIDMSTX TIDMSTXW
RNS Number : 2719G
Shield Therapeutics PLC
04 August 2016
Shield Therapeutics plc
("Shield" or the "Company")
Result of Annual General Meeting
London, UK, 04 August 2016. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces that at its Annual General Meeting held today, all resolutions were duly passed.
- Ends -
For further information please contact:
Shield Therapeutics plc +44 (0)191 511 8507 Carl Sterritt, Chief Executive Officer Richard Jones, Chief Financial Officer NOMAD Liberum Capital Limited Christopher Britton Steve Pearce Jamil Miah +44 (0)20 3100 2222 Financial PR Advisor +44 (0)203 709 5700 Consilium Strategic Communications shieldtherapeutics@consilium-comms.com Mary-Jane Elliott Matthew Neal Lindsey Neville Hendrik Thys
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The Company has an approved product, Feraccru(R), for the treatment of iron deficiency anaemia (IDA). In addition, the Company has a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia), PT20. Shield, based in London and Newcastle, joined AIM in 2016 under the ticker STX. For more information please visit www.shieldtherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGAKQDKKBKDBFK
(END) Dow Jones Newswires
August 04, 2016 06:05 ET (10:05 GMT)
1 Year Shield Therapeutics Chart |
1 Month Shield Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
